Active, not recruitingPHASE1, PHASE2NCT04261855

Targeted Therapy and Avelumab in Merkel Cell Carcinoma

Studying Cutaneous neuroendocrine carcinoma

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Melanoma and Skin Cancer Trials Limited
Principal Investigator: Prof Shahneen Sandhu, MBBS, FRACP
Peter MacCallum Cancer Centre, Australia
Intervention: Avelumab(drug)
Enrollment: 19 enrolled
Eligibility: 18 years · All sexes
Timeline: 2020 – 2027

Study locations (10)

Mid North Coast Cancer Institute - Coffs Harbour Health Campus, Coffs Harbour, New South Wales, Australia
Lake Macquarie Private Hospital, Gateshead, New South Wales, Australia
Gosford Hospital, Gosford, New South Wales, Australia
Wyong Hospital, Hamlyn Terrace, New South Wales, Australia
Royal North Shore Hospital, Sydney, New South Wales, Australia
Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
Princess Alexandra Hospital, Brisbane, Queensland, Australia
Royal Adelaide Hospital, Adelaide, South Australia, Australia
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Sir Charles Gaidner Hospital, Perth, Western Australia, Australia

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04261855 on ClinicalTrials.gov

Other trials for Cutaneous neuroendocrine carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Cutaneous neuroendocrine carcinoma →

← Back to all trials